BRIEF-FDA approves Genentech's MS drug Ocrevus
* FDA approves Genentech's Ocrevus (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis
Feb 10 Ortivus Ab:
* Q4 revenue 22.9 million Swedish crowns ($2.57 million) versus 13.8 million crowns year ago
* Q4 EBITDA 5.7 million crowns versus 3.5 million crowns year ago
* Proposes no dividend for 2016 Source text for Eikon: Further company coverage: ($1 = 8.9007 Swedish crowns) (Gdynia Newsroom)
WASHINGTON, March 28 U.S. President Donald Trump told a group of senators on Tuesday that he expected lawmakers would be able to reach a deal on healthcare, without offering specifics on how they would do it or what had changed since a healthcare reform bill was pulled last week for insufficient support.